How should hemolytic anemia in a patient with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency be managed?

Management of Hemolytic Anemia in G6PD Deficiency

The cornerstone of managing hemolytic anemia in G6PD-deficient patients is immediate discontinuation of the offending oxidant trigger, supportive care with IV hydration and oxygen, and avoidance of methylene blue, which is absolutely contraindicated and can paradoxically worsen hemolysis. 1

Immediate Management of Acute Hemolytic Crisis

First-Line Actions

• Stop the oxidant trigger immediately upon recognition of hemolysis—this is the single most critical intervention to prevent progression 1
• Provide aggressive IV hydration to maintain renal perfusion and prevent acute kidney injury from hemoglobinuria 1
• Administer supplemental oxygen for any patient with respiratory symptoms, hypoxia, or significant anemia 1
• Monitor laboratory parameters closely: hemoglobin, reticulocyte count, bilirubin, LDH, and haptoglobin to assess severity and response 1

Severe Hemolysis Requiring Advanced Intervention

• Exchange transfusion should be considered for life-threatening hemolysis with severe anemia, hemodynamic instability, or renal compromise 1, 2
• Simple blood transfusion may be adequate for moderate hemolysis with symptomatic anemia but stable vital signs 3

Critical Medication Contraindications

Absolute Contraindications (High-Risk Oxidants)

• Methylene blue is absolutely contraindicated in G6PD deficiency—it is ineffective for treating methemoglobinemia in these patients and will worsen hemolysis due to insufficient NADPH for reduction 2, 1, 3
• Rasburicase must be avoided in all G6PD-deficient patients due to severe hemolysis risk and potential methemoglobinemia 4, 1, 5
• Dapsone should not be used as it causes severe oxidative hemolysis 1, 6, 7
• Primaquine courses >5 days are contraindicated in all G6PD variants; short courses ≤5 days may be tolerated only in the milder African A- variant but remain high-risk 1

Medium-Risk Medications (Use with Extreme Caution)

• Sulfonamides (including sulfamethoxazole/cotrimoxazole) require careful risk-benefit assessment, though real-world data suggest they may be safer than previously thought in some patients 1, 8
• Nitrofurantoin has been prescribed safely to over 1,300 G6PD-deficient patients in real-world studies, but caution is still warranted 8

Safe Medications

• Acetaminophen/paracetamol is safe and can be used without restriction 1
• Chloroquine is safe for malaria treatment, including in pregnant G6PD-deficient women 1

Variant-Specific Risk Stratification

Mediterranean (B-) Variant

• Carries the highest risk of life-threatening hemolysis with <10% residual enzyme activity 1
• All oxidant drugs must be strictly avoided in this population 1

African (A-) Variant

• Milder deficiency with 10-60% residual enzyme activity 1
• Short-course primaquine (≤5 days) may be tolerated, but longer courses and other high-risk agents remain contraindicated 1

Management of Concurrent Methemoglobinemia

When methemoglobinemia occurs in a G6PD-deficient patient (a rare but serious complication):

• Do NOT use methylene blue—it will worsen hemolysis and is ineffective 2, 1, 3
• Administer high-dose intravenous ascorbic acid as first-line therapy (0.2-1.0 g/day in divided doses) 2, 1
• Exchange transfusion is the definitive treatment for severe methemoglobinemia refractory to ascorbic acid, with 81.6% survival rate 2
• Hyperbaric oxygen therapy is an alternative for refractory cases 2

Special Population: Pregnancy

• Chloroquine remains safe for malaria treatment in pregnant G6PD-deficient women 1
• Primaquine must be avoided throughout pregnancy due to unknown fetal safety and risk of fetal hemolysis 1
• Methylene blue is contraindicated due to teratogenic risk (intestinal atresia) and potential fetal hemolysis 1

Screening Before High-Risk Drug Administration

• Mandatory G6PD testing is required before prescribing primaquine, dapsone, rasburicase, or sulfonamides to individuals of African, Mediterranean, Middle Eastern, or Southeast Asian ancestry 1
• Quantitative enzymatic assays are preferred over qualitative spot tests for accurate classification, especially in females (who may be heterozygous) and intermediate-deficiency cases 1

Common Pitfall: Diabetes-Related Hemolysis

• Rapid correction of severe hyperglycemia in newly diagnosed diabetes can trigger hemolytic crisis in undiagnosed G6PD-deficient patients 9, 10
• Screen for G6PD deficiency in areas with high prevalence before aggressively correcting hyperglycemia 9
• Correct glucose gradually if G6PD deficiency is known to avoid rapid decline in glucose availability to red cells 9

Patient Education Essentials

• Provide a written list of high-risk medications (primaquine >5 days, dapsone, methylene blue, rasburicase, sulfonamides) to carry at all times 1
• Instruct patients to seek immediate care for dark urine, jaundice, fatigue, dyspnea, or back pain—these are signs of hemolysis requiring urgent evaluation 1
• Warn about fava bean ingestion, which remains the most common trigger of major hemolysis (71.8% of hospitalized cases) 8